tirzepatide renal impairment effects of GLP-1 receptor agonists and in individuals with type 2 diabetes: seeds of a promising future | Endocrine tirzepatide chronic kidney disease trial

The primary endpoint was the change in AHI, with secondary endpoints including changes in body weight, hypoxic burden, sleep-related impairment, high-sensitivity C-reactive protein (hsCRP) concentration, and systolic blood pressure

Journal Reference : Kezia Peter, Ocin Roka, Emma Sepp, Maya Warburton, Jufen Zhang, Simon C

doi: 10.1074/jbc.M109.089433 56 Di MeglioT.KratochwilC

Growth Hormone Stimulating Peptide Therapy (Sermorelin, Ipamorelin, CJC1295, etc.) As you age, your quality of life may start to decline

Predicted physicochemical properties supported its hydrophobic character and oral bioavailability, suggesting it is a metabolically stable and BBB-permeable molecule [1]